Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast

Annals of Clinical and Laboratory Science

Volumn 39, Issue 1, 2009, Pages 17-24

  Lester, Todd ^a   Wang, Jianmin ^b,c   Bourne, Patricia ^a   Yang, Qi ^a   Fu, Li ^a   Tang, Ping ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

AR; Cytokeratin markers; EGFR; ER; HER2; Mammary paget's disease; PR

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RECEPTOR ANTIBODY;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; NIPPLES; PAGET'S DISEASE, MAMMARY; TUMOR MARKERS, BIOLOGICAL;

EID: 60249090945     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Paget J. On disease of the mammary areola preceding cancer of the mammary gland. St Bartholomew's Hospital Report 1874;10:87-89.
2. Eusebi V, Mai KT, Taranger-Charpin A. Tumours of the nipple. Tumours of the breast and female genital organs, WHO Classification of Tumours, 2003 (Tavassoli FA, Devilee P., Eds), WHO, Geneva 2003; pp 104-106.
3. Chen CY, Sun LM, Anderson BO. Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer 2006;107:1448-1458.
4. Liegl B, Leibl S, Gogg-Kamerer MG, Tessaro B, Horn L-C, Moinfar F. Mammary and extramammary Paget's disease: an immunohistochemical study of 83 cases. Histopathology 2007;50:439-447.
5. Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. J Clin Pathol, 2000;53:742-749.
6. Yim JH, Wick MR, Philpott GW, Norton JA, Doherty GM. Underlying pathology in mammary Paget's disease. Ann Surg Oncol 1997;4:287-292.
7. Mai KT, Yazdi HM, Perkins DG. Mammary Paget's disease: evidence of diverse origin of the disease with a subgroup of Paget's disease developing from the superficial portion of the lactiferous duct and a discontinuous pattern of tumor spread. Pathol Int 1999; 49:956-961.
8. Chaudary MA, Millis RR, Lane EB, Miller NA. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat 1986;8:139-146.
9. Fu W, Lobocki CA, Silbergerg BK, Chelladurai M, Young SC. Molecular markers in Paget disease of the breast. J Surg Oncol 2001;77:171-178.
10. Reed W, Oppedal BR, Larsen TE. Immunohistology is valuable in distinguishing superficial spreading melanoma. Histo-pathology 1990;35:583-588.
11. Kanitakis J. Mammary and extramammary Paget's disease. J Europ Acad Derm Venereol 2007;21:581-590.
12. Vielh P, Validire P, Kheirallah S, Campana F, Fourquet A, Di Bonito L. Paget's disease of the nipple without clinically and radiologically detectable breast tumor. Histochemical and immunohistochemical study of 44 cases. Pathol Res Pract 1993;189:150-155.
13. Paone JF, Baker RR. Pathogenesis and treatment of Paget's disease of the breast. Cancer 1981;48:825-829.
14. Toker C. Clear cells of nipple epidermis. Cancer 1970; 25:601-610.
15. Marucci G, Betts CM, Golouh R, Peterse JI, Foschini MP, Eusebi V. Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description. Virchows Arch 2002;441:117-123.
16. Morandi L, Pession A, Marucci GL, Foschini MP, Pruneri G, Viale G, Eusebi V. Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. Hum Pathol 2003;34:1321-1330.
17. Bhargava R, Dabbs D. Use of immunohistochemistry in diagnosis of breast epithelial lesions. Advan Anat Pathol 2007;14:93-107.
18. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
19. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.
20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SZ, Lenning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portrait of human breast tumours. Nature 2000;406:747-752.
21. Sortil T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinoma distinguish tumor subclasses with clinical implications. PNAS 2001;98:10869-10874.
22. Sorlie T, Tibshirani R, Parker J, Hestie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 2003;100:8418-8423.
23. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, Herbst H, Schmidt A, Lerch MM, Buchwalow IB. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002;198:458-467.
24. Megha T, Ferrari A, Benvenuto A, Bellan C, Lalinga AV, Lassi S, Bartolommei S, Cevenini G, Leoncini L, Tosi P. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 2002;55:461-466.
25. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
26. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-180.
27. Gunhan-Bilgen I, Oktay A. Paget's disease of the breast: clinical, mammographic, sonographic and pathologic findings in 52 cases. Euro J Radiol 2006;60:256-263.
28. Zakaria S, Pantvaidya C, Ghosh K, Degnim AC. Paget's disease of the breast: accuracy of preoperative assessment. Breast Cancer Res Treat 2007;102:137-142.
29. Frei KA, Bonel HM, Pelte MF, Hylton NM, Kinkel K. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol 2005;40:363-367.
30. Keatings L, Sinclair J, Wright C, et al. c-erbB-2 onco-protein expression in mammary and extramammary Paget's disease: an immunohistochemical study. Histopathol 1990;17:243-247.
31. Bianco MK, Vasef MA. HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study. Diagn Mol Pathol 2006;15:131-135.
32. Schelfhout VRJ, Coene ED, Delaey B, Thys S, Page DL, De Potter CR. Pathogenesis of Paget's disease: epidermal heregulin-α, motility factor, and the HER receptor family. J at Can Inst 2000;92:622-628.
33. Liegl B, Horn LC, Moinfar F. Androgen receptors are frequently expressed in mammary and extramammary Paget's disease. Modern Pathol 2005;18:1283-1288.